Maisels L, Steinberg J, Tobias C
Medicaid Working Group/Boston University School of Public Health, Boston, Massachusetts 02210, USA.
AIDS Patient Care STDS. 2001 Apr;15(4):185-91. doi: 10.1089/10872910151133701.
Treatment with highly active antiretroviral therapy (HAART) decreases morbidity and mortality for persons with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and reduces costs of care. Yet many patients for whom HAART is indicated do not receive it. This study investigated the reasons why certain patients of a community health center with HIV/AIDS did not receive HAART between 1997 and 1998. Medical record reviews were performed to determine which patients for whom HAART was indicated (according to United States Public Health Service guidelines) were not prescribed HAART. Chart reviews and patient interviews were conducted to determine why they did not receive HAART. Of the 88 patients eligible for HAART, 60 (69%) had it prescribed in 1997-1998. Of the remaining 28 patients, 3 did not receive HAART because their provider never discussed it with them. For 6 patients (21%), the provider discussed HAART but did not recommend it; 16 patients (57%) declined HAART although their provider recommended it, and 3 (11%) accepted their provider's recommendation but never started HAART. Patients' most common reasons for refusing HAART were not being ready for strict adherence to a complex regimen (7/16) and fear of side effects (6/16). Other reasons included active drug use, religious beliefs, homelessness, confidentiality concerns, depression, and feeling well without HAART. Providers did not recommend HAART because of active drug use (4/6), lack of engagement with care (2/6) as well as homelessness, depression, and the perception that the patient was doing well without HAART. Providers should be trained to offer all patients the opportunity to develop a plan to address barriers to adherence and the support needed to implement it. Resources should also target the treatment of substance abuse and mental illness to improve the usage of HAART.
高效抗逆转录病毒疗法(HAART)可降低人类免疫缺陷病毒/获得性免疫缺陷综合征(HIV/AIDS)患者的发病率和死亡率,并降低护理成本。然而,许多符合HAART治疗指征的患者并未接受该治疗。本研究调查了1997年至1998年间某社区卫生中心的某些HIV/AIDS患者未接受HAART治疗的原因。通过查阅病历以确定哪些符合HAART治疗指征(根据美国公共卫生服务指南)的患者未被开具HAART处方。进行病历审查和患者访谈以确定他们未接受HAART治疗的原因。在88例符合HAART治疗条件的患者中,60例(69%)在1997 - 1998年期间被开具了该治疗处方。在其余28例患者中,3例未接受HAART治疗是因为他们的医疗服务提供者从未与他们讨论过;6例患者(21%),医疗服务提供者讨论了HAART但未推荐;16例患者(57%)尽管医疗服务提供者推荐了HAART,但仍拒绝接受;3例(11%)接受了医疗服务提供者的推荐但从未开始使用HAART。患者拒绝HAART最常见的原因是尚未准备好严格遵守复杂的治疗方案(7/16)和担心副作用(6/16)。其他原因包括正在吸毒、宗教信仰、无家可归、担心隐私、抑郁以及在未接受HAART治疗的情况下感觉良好。医疗服务提供者不推荐HAART治疗的原因包括正在吸毒(4/6)、缺乏对治疗的参与度(2/6)以及无家可归、抑郁,还有认为患者在未接受HAART治疗的情况下情况良好。应培训医疗服务提供者为所有患者提供制定应对依从性障碍计划及实施该计划所需支持的机会。资源还应针对药物滥用和精神疾病的治疗,以提高HAART的使用率。
AIDS Patient Care STDS. 2001-4
J Acquir Immune Defic Syndr. 1999-6-1
J Acquir Immune Defic Syndr. 2000-4-15
Verh K Acad Geneeskd Belg. 2001
J Gen Intern Med. 2003-4
J Assoc Nurses AIDS Care. 2007
AIDS Patient Care STDS. 2004-2
JMIR Mhealth Uhealth. 2016-3-15
Qual Health Res. 2015-12
AIDS Res Ther. 2014-1-24